THERAPY DOSSIER · th-842960bf75b6

Cyclic helix B peptide (CHBP), a thioether-cyclised erythropoietin-derived helix B surface peptide

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30911412 ↗2019Reported benefit

Cyclic helix B peptide ameliorates acute myocardial infarction in mice by inhibiting apoptosis and inflammatory responses.

MouseIschaemia-reperfusionCardiacC57B6 (C57BL/6)Malen = Short-term arm: 3 groups, n = 10 per group; long-term arm:…Intraperitoneal30 micrograms/kgImmediately after coronary artery ligation surgery

Model: Acute myocardial infarction by permanent ligation of the left anterior descending coronary artery with 10/0 silk suture, 1 mm distal to the left atrial appendage

CHBP reduced histological injury, infarct size and serum CK-MB, increased survival, reduced cardiomyocyte apoptosis, increased ejection fraction and wall thickness while reducing left ventricular end-diastolic volume, lowered pro-inflammatory cytokines and raised IL-4, IL-9 and IL-10 at both 24 hou…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…